Denali Therapeutics Inc (DNLI)

NASDAQ
Currency in USD
13.78
-0.38(-2.68%)
Closed·
After Hours
13.99+0.21(+1.52%)
·
DNLI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
DNLI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.6914.24
52 wk Range
10.5733.33
Key Statistics
Edit
Prev. Close
14.16
Open
14.15
Day's Range
13.69-14.24
52 wk Range
10.57-33.33
Volume
1.09M
Average Vol. (3m)
1.43M
1-Year Change
-31.92%
Book Value / Share
7.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DNLI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
32.25
Upside
+134.03%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings upwards for the upcoming period
Show more

Denali Therapeutics Inc Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Compare DNLI to Peers and Sector

Metrics to compare
DNLI
Peers
Sector
Relationship
P/E Ratio
−4.4x−2.9x−0.5x
PEG Ratio
0.03−0.010.00
Price / Book
1.8x1.6x2.6x
Price / LTM Sales
-17.9x2.9x
Upside (Analyst Target)
125.0%259.9%49.4%
Fair Value Upside
Unlock4.9%8.2%Unlock

Analyst Ratings

19 Buy
0 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 32.25
(+134.03% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-0.78 / -0.70
Revenue / Forecast
-- / 1.70M
EPS Revisions
Last 90 days

People Also Watch

169.49
LANC
+1.53%
38.87
AKRO
-2.73%
59.31
NXT
-3.70%
17.89
BEAM
+3.71%
136.88
QLYS
+0.72%

FAQ

What Is the Denali Therapeutics (DNLI) Stock Price Today?

The Denali Therapeutics stock price today is 13.78

What Stock Exchange Does Denali Therapeutics Trade On?

Denali Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Denali Therapeutics?

The stock symbol for Denali Therapeutics is "DNLI."

What Is the Denali Therapeutics Market Cap?

As of today, Denali Therapeutics market cap is 2.00B.

What Is Denali Therapeutics's Earnings Per Share (TTM)?

The Denali Therapeutics EPS (TTM) is -2.67.

When Is the Next Denali Therapeutics Earnings Date?

Denali Therapeutics will release its next earnings report on Jul 31, 2025.

From a Technical Analysis Perspective, Is DNLI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.